BIMZELX<sup>®</sup> (Bimekizumab-bkzx) Injection, for Subcutaneous Use.
Bibliographic record
Abstract
(bimekizumab-bkzx) injection, for subcutaneous use, was approved in October 2023 for moderate to severe plaque psoriasis in patients aged ≥18 years. In three phase 3, randomized, double-blind, vehicle, and comparator-controlled studies (Be Vivid, Be Ready, and Be Sure), bimekizumab was investigated for the treatment of plaque psoriasis. The primary efficacy end point was psoriatic area and severity index (PASI) 90 (patients with 90% improvement in PASI from baseline) and investigator's global assessment (IGA) score of 0 (clear skin)-1 (almost clear skin) as well as ≥2-point improvement from baseline at week 16. In the Be Vivid study, patients were randomized into the bimekizumab, placebo, and ustekinumab groups. PASI 90 score was achieved by 85% (273/321) in the bimekizumab group, 5% (4/83) in the placebo group, and 50% (81/163) in the ustekinumab group. IGA 0/1 score was achieved by 84% (270/321) in the bimekizumab group, 5% (4/83) in the placebo group, and 53% (87/163) in the ustekinumab group. In the Be Ready study, patients were randomized into bimekizumab and placebo groups. PASI 90 score was achieved by 91% (317/349) in the bimekizumab group and 1% (1/86) in the placebo group. IGA 0/1 score was achieved by 93% (323/349) in the bimekizumab group and 1% (1/86) in the placebo group. In the Be Sure study, patients were randomized into two bimekizumab groups (receiving different bimekizumab regimens) and one adalimumab group. PASI 90 score was achieved by 86.2% (275/319) in combined bimekizumab groups and 47.2% (75/159) in the adalimumab group. IGA 0/1 score was achieved by 85.3% (272/319) in combined bimekizumab groups and 57.2% (91/159) in the adalimumab group. Bimekizumab was well tolerated with no unexpected safety findings.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.000 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.025 | 0.008 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".